OPT Opthea Ltd: Market Capitalization to Book Value Ratio

The stability of Opthea Limited (OPT) relies on the potential of sozinibercept in treating AMD, which is confirmed by the price-to-book multiplier chart, where the indicator value reaches -3.07. The operational base is built on competing with global ophthalmology leaders, while the production of biologics for current tests is fully outsourced to external contract manufacturing organizations.

The mvsbcap_co ratio compares the market value of Opthea Limited (OPT) to the book value of its net assets. This metric determines the size of the premium the market is willing to pay for the business's future potential. Since the development of retinal therapies is independent of economic cycles, the company's valuation is driven by the success of clinical trials. By analyzing the company's valuation history via the P/B ratio, an investor can timely identify risks of operating margin compression.